Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Ghirardi, P; Brusoni, B; Mangiavacchi, Maurizio; Bianco, Lucia Dal; Col, Jacques; Metra, Marco; Dei, Livio

doi:10.1111/j.1365-2125.1985.tb02688.x

Cited by 9 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCP: pulmonary capillary pressure (data obtained from Rajferet al [36]). diac index, stroke work index, pulmonary artery pressure and systemic vascular resis tance were statistically correlated with the dose of ibopamine [26]. but maximal epinine plasma levels do not correspond to maximal pharmacologic activity of ibopamine.…”

Section: Pcpmentioning

confidence: 88%

See 1 more Smart Citation

Hemodynamic and Neurohumoral Effects of Ibopamine in Patients with Chronic Congestive Heart Failure

López‐Sendón

1990

Cardiology

View full text Add to dashboard Cite

Ibopamine is a new, orally active dopamine-like drug with inotropic and vasoac-tive properties. With a predominant action on dopaminergic (DA) and β-receptors, ibopamine increases cardiac output, reduces peripheral vascular resistances and increases renal blood flow, exerting a lesser effect on preload parameters. This hemodynamic improvement is manifested in subjects with normal myocardium as well as in patients with heart failure in different stages of the syndrome including refractory heart failure, and it is also present after relatively long-term treatment without evidence of pharmacological tolerance. Probably in relation with DA₂ activation, ibopamine also modulates the neurohumoral consequences of heart failure with a decrease in plasma renin activity and norepinephrine and aldosterone plasma levels, both acutely and after chronic administration, an effect that can be beneficial in the long-term treatment of patients with chronic congestive heart failure.

show abstract

Section: Pcpmentioning

confidence: 88%

“…34] (fig.3). effect compared with nitroprusside Ghirardi [26] 10 111:3. IV:7 100-200 = = +33 -1 7 No* -24 dose-related effect Nakano [27] 11 E .1 …”

Section: Pcpmentioning

confidence: 99%

Hemodynamic and Neurohumoral Effects of Ibopamine in Patients with Chronic Congestive Heart Failure

López‐Sendón

1990

Cardiology

View full text Add to dashboard Cite

show abstract

“…Epinine is known to stimulate dopamine receptors and to a lesser degree adrenergic receptors (Nichols et al, 1987;Rajfer et al, 1986). Ibopamine is mainly used in patients with congestive heart failure (Ghirardi et al, 1985;Van Veldhuisen et al, 1989). In healthy volunteers no renal function studies have been performed with simultaneous measurements of GFR and ERPF.…”

Section: Introductionmentioning

confidence: 99%

Renal and neurohumoral effects of ibopamine and metoclopramide in normal man.

Girbes¹,

Veldhuisen

Smit

et al. 1991

Brit J Clinical Pharma

View full text Add to dashboard Cite

The effects of 100 mg ibopamine, an orally active nonselective dopamine agonist on renal haemodynamics, sodium excretion, blood pressure (BP), heart rate (HR) and neurohumoral parameters were investigated in 10 healthy volunteers, with and without metoclopramide pretreatment. A small and temporary rise of glomerular filtration rate (GFR) was found after ibopamine without but not with metoclopramide pretreatment. No differences in effective renal plasma flow (ERPF) but a small rise in sodium excretion were observed comparing ibopamine with control. Metoclopramide induced a fall in sodium excretion which was not reversed by ibopamine. Ibopamine failed to affect BP and HR and no changes of PRA or plasma aldosterone concentration (PAC) were found. Metoclopramide induced a pronounced increase of PAC which was blunted by ibopamine. Plasma and urinary catecholamines were unchanged for all study days. We conclude that ibopamine induces natriuresis probably not by the observed small and temporary renal haemodynamic effects but by direct stimulation of DA1 dopamine receptors in the proximal tubule.

show abstract

“…Its effects on beta-2-and alpha-receptors are small [3]-(e) Dopexamine (IV) is a promising new dopaminergic agonist [4], (f) Ibopamine offers the possibility to ob tain the dopamine response with the advan tage of selective renal vasodilation. In con trast with the preceding two drugs, it can be administered orally [5].…”

Section: Improving Contractile Performancementioning

confidence: 99%

Treatment of Congestive Heart Failure: Pharmacological Principles

Kulbertus¹

1988

Cardiology

View full text Add to dashboard Cite

Heart failure may result from different aetiologies: excessive afterload, depressed intrinsic contractility (generalized or regional), volume overload, and changes in diastolic properties. Compensatory mechanisms, such as the reflex increase in sympathetic tone, may initially be beneficial, but, in the long run, may become deleterious. Thus heart failure represents a very complex situation. Treatment should aim at: (a) removing the cause of heart failure; (b) improving contractile performance (by enhancement of the intrinsic contractile properties or by decreasing afterload); (c) moderating the major symptom-producing features (increased filling pressure), and decreasing peripheral demands for cardiac output.

show abstract

Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

Cited by 9 publications

References 15 publications

Hemodynamic and Neurohumoral Effects of Ibopamine in Patients with Chronic Congestive Heart Failure

Hemodynamic and Neurohumoral Effects of Ibopamine in Patients with Chronic Congestive Heart Failure

Renal and neurohumoral effects of ibopamine and metoclopramide in normal man.

Treatment of Congestive Heart Failure: Pharmacological Principles

Contact Info

Product

Resources

About